Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia ...
The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a ...
Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO.O), opens new tab jumped nearly 16% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the ...
Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a phase 3 trial of its sickle cell disease (SCD) therapy mitapivat, sending ...
French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic ...
Dec 24 (Reuters) - Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a ...
Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of ...
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular ...
The FDA approved expanded use of mitapivat for alpha- and beta-thalassemia patients. Shares jumped nearly 15% in premarket trading. Analysts see meaningful revenue upside despite safety monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback